- CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody - Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potential best-in-class, clinical stage anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today announced that data will be presented fro ...

Accessibility StatementSkip Navigation Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced immunosuppression representing a new target in overcoming acquired resistance to cancer immunotherapy The first demonstration that DOR is expressed on Tumor-Associated Macrophages (TAMs), with DOR inhibition modulating their immunosuppressive capabilities Presentation from The Mof ...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on mitapivat, an oral pyruvate kinase (PK) activator, will be featured in oral and poster presentations during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (ASH 2025) in Orlando, Florida, December 6-9, 2025. “This year’s presentations ...

REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will be featured in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida. The presentation will highlight additional ...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translational data from the Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL314) for the treatment of aggressive large B-cell lymphoma (LBCL) will be presented at the 67th American Society of ...

WILMINGTON, Del., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) has changed the start time of its fourth-quarter fiscal 2025 earnings webcast being held on Wednesday, November 5, 2025. The event will now begin at 10:00 a.m. ET instead of 9:00 a.m. ET.  Attendees that have previously registered do not need to register again. The company’s live webcast with securities analysts will include an executive summary and detailed remarks. Simultaneously, the company will post a slide presentation in th ...

Core Points - Ashland Inc. plans to release its fourth-quarter fiscal 2025 earnings on November 4, 2025, at approximately 5 p.m. ET [1] - A live webcast for securities analysts will occur on November 5, 2025, at 9 a.m. ET, featuring an executive summary and detailed remarks [1] - The webcast and supporting materials will be available on Ashland's Investor Relations website, with an archived version accessible for 12 months post-event [3] Company Overview - Ashland Inc. is a global additives and specialty ingredients company focused on environmental, social, and governance (ESG) initiatives [4] - The company serves diverse markets, including architectural coatings, construction, energy, food and beverage, personal care, and pharmaceuticals [4] - Ashland employs approximately 2,960 professionals, including scientists, research chemists, engineers, and plant operators, to develop innovative solutions for customers in over 100 countries [4]

Core Insights - Ashland Inc. has appointed Sandy Klugman as the new director of Investor Relations, effective October 13, 2025, reporting to CFO William Whitaker [1][4]. Summary by Sections Appointment Details - Sandy Klugman joins Ashland with over 20 years of experience in investor relations, equity research, and investment analysis, and is a CFA charterholder [2]. - His previous role was as senior vice president of Investor Relations at ICR Strategic Communications and Advisory, where he advised various companies on investor relations strategies [2]. Professional Background - Klugman has a strong track record in developing investor engagement programs and crafting corporate narratives, with experience in both sell-side and buy-side equity analysis [3]. - He has worked with notable firms such as Susquehanna Financial Group, Credit Suisse, and UBS Securities, focusing on agriculture and chemicals sectors [3]. Educational Qualifications - Klugman holds an MBA in Finance and Accounting from the University of Chicago Booth School of Business and a Bachelor of Science in Communication from Cornell University [4]. Company Overview - Ashland Inc. is a global additives and specialty ingredients company, emphasizing environmental, social, and governance (ESG) principles [5]. - The company serves a diverse range of markets, including architectural coatings, construction, energy, food and beverage, personal care, and pharmaceuticals, employing approximately 2,960 professionals [5].

Core Insights - The international beauty raw material companies are facing significant challenges in 2025 due to global economic instability and unfavorable currency exchange rates, which have become the primary obstacle to growth [1][3] - Despite the challenges, there is still a vibrant innovation landscape in the beauty raw materials sector, driven by scientific advancements and a shift in consumer preferences towards effective and clinically validated ingredients [1][5] Financial Performance - BASE reported a total sales of €33.2 billion with a beauty raw materials segment sales of €2.468 billion, showing a year-on-year increase [2] - BASF experienced a slight decline in overall sales by 1.48% but saw a growth of 3.6% in its beauty raw materials segment [2] - Clariant's sales in beauty raw materials were not disclosed, while Symrise reported €2.554 billion in total sales with a 9.89% increase in its beauty raw materials segment [2] Market Trends - The beauty raw materials market is increasingly influenced by consumer demand for scientifically backed ingredients, moving away from mere ingredient trends to a focus on efficacy and clinical validation [4][5] - The rise of "neurocosmetics" is notable, with companies like DSM-Firmenich and Croda developing ingredients that not only enhance skin appearance but also positively affect emotional well-being [9][10] Innovation and R&D - Companies are investing in extensive R&D to develop active ingredients that meet the evolving market demands, with a focus on scientific validation and consumer experience [12][14] - The development of a comprehensive scientific framework for new ingredients is becoming essential, as companies aim to provide clear efficacy and safety data to consumers [12][15] Localization and Market Adaptation - International raw material companies are increasingly localizing their R&D and production in China to better cater to local consumer preferences and market dynamics [14][15] - Companies are also enhancing their scientific communication and service systems to build long-term value and support clients in navigating the complex beauty ingredient landscape [15]

Core Insights - The international beauty raw material companies are facing significant challenges in 2025 due to global economic fluctuations and unfavorable currency exchange rates, which have become the primary obstacle to growth [2][5] - Despite some growth in the beauty and personal care sectors, these companies are encountering new competitive pressures in the Chinese market, prompting a focus on innovation driven by scientific research [3][11] Financial Performance - The financial reports for the first half of 2025 show varying degrees of performance among international raw material companies, with overall sales and EBITDA experiencing fluctuations [5][6] - For instance, BASF reported a slight decline in overall sales by 1.48% but a growth of 3.6% in beauty raw materials, while DSM-Firmenich saw a 3.37% increase in overall sales but a decline in beauty raw materials by 0.89% [6] Market Trends - The Chinese market is viewed as a key opportunity for international raw material companies, despite increasing competition, as consumer preferences shift towards scientifically validated ingredients rather than trendy components [11][12] - The trend towards "scientific skincare" is pushing companies to develop active ingredients with clear scientific backing and clinical validation [14][21] Innovation and R&D - Companies are investing in advanced technologies and innovative ingredients tailored to the unique demands of the Chinese market, such as neurocosmetics that address emotional well-being and skin health [17][18] - The rise of neurocosmetics is evident, with a significant increase in products that offer emotional benefits, reflecting a shift in consumer focus from mere efficacy to sensory experiences [19][20] Strategic Approaches - International raw material companies are adopting a long-term approach to innovation, emphasizing foundational research and the development of a comprehensive scientific framework for their products [21][24] - Companies like DSM and Clariant are localizing their R&D efforts in China, aiming to create products that resonate with local consumer needs while building a robust scientific communication framework [26][27]